Decibel Therapeutics Inc
DBTX
|
$4.91
-0.81%
-0.2%
0
|
Health Technology
(0.0% 1d) (0.0% 1m) (91.8% 1y) (-0.8% 2d) (-1.4% 3d) (0.0% 7d) (283.12% volume)
Earnings Calendar: 2023-11-09
Market Cap: $ 123,373,251
https://www.decibeltx.com
Sec Filling | Patents | 40 employees
Decibel Therapeutics is a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, one of the largest areas of unmet need in medicine. Decibel has built a proprietary platform that integrates single-cell genomics and bioinformatic analyses, precision gene therapy technologies and expertise in inner ear biology. Decibel is leveraging its platform to advance gene therapies designed to selectively replace genes for the treatment of congenital, monogenic hearing loss and to regenerate inner ear hair cells for the treatment of acquired hearing and balance disorders. Decibel’s pipeline, including its lead gene therapy program, DB-OTO, to treat congenital, monogenic hearing loss, is designed to deliver on our vision of a world in which the privileges of hearing and balance are available to all.
urea ceiling treatment gene therapies t-cell
add to watch list Paper trade email alert is off
Athenex, Inc.
ATNX
|
$0.2031
-7.78%
1.9M
|
Health Technology
(0.0% 1d) (0.0% 1m) (-85.9% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (199.02% volume)
Earnings Calendar: 2022-10-27
Market Cap: $ 1,759,498
http://www.athenex.com
Sec Filling | Patents | 574 employees
(US) Athenex, Inc. is a biopharmaceutical company, which engages in the discovery, development and commercialization of novel therapies for the treatment of cancer. It operates through the following segments: Oncology Innovation Platform, Global Supply Chain Platform, and Commercial Platform. The Oncology Innovation Platform segment focuses on the research and development of proprietary drugs. The Global Supply Chain Platform segment provides supply of active pharmaceutical ingredients (APIs) for clinical and commercial efforts. The Commercial Platform segment involves in the sales and marketing of specialty drugs and market development of proprietary drugs. The company was founded by Lyn M. Dyster and David G. Hangauer in November 2003 and is headquartered in Buffalo, NY.
cancer tirbanibulin treatment
add to watch list Paper trade email alert is off
Baudax Bio, Inc.
BXRX
|
$0.1864
-54.35%
330K
|
Health Technology
(0.0% 1d) (0.0% 1m) (-92.4% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (-0.34% volume)
Earnings Calendar: 2022-11-10
Market Cap: $ 1,710,656
http://www.baudaxbio.com
Sec Filling | Patents | 25 employees
Baudax Bio, Inc. is a pharmaceutical company focusing on developing and commercializing products for acute care settings. The company was founded in 2015 and is headquartered in Malvern, PA.
Drugs
Anjeso (meloxicam)add to watch list Paper trade email alert is off
Heska Corporation
HSKA
|
$119.99
0.0%
390K
|
Health Technology
(0.0% 1d) (0.0% 1m) (2.2% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (87.26% volume)
Earnings Calendar: 2023-08-08
Market Cap: $ 1,309,541,342
http://www.heska.com
Sec Filling | Patents | 386 employees
(US) Heska Corp. engages in the provision of veterinary and animal health diagnostic, and specialty products. It operates through two segments: Core Companion Animal Health and Other Vaccines & Pharmaceuticals. The Core Companion Animal Health segment includes point of care diagnostic laboratory instruments and supplies, imaging instruments, software, and services as well as single use diagnostic and other tests, pharmaceuticals, and vaccines. The Other Vaccines & Pharmaceuticals segment focuses on private label vaccine and pharmaceutical production, primarily for cattle, but also for equine, porcine, avian, feline, and canine. Heska was founded by Robert B. Grieve and Lynnor B. Stevenson in 1988 and is headquartered in Loveland, CO.
vaccine animals diagnostics veterinary
add to watch list Paper trade email alert is off
Checkmate Pharmaceuticals, Inc.
CMPI
|
$10.5
0.0%
|
Health Technology
(0.0% 1d) (0.2% 1m) (0.0% 1y) (0.2% 2d) (0.1% 3d) (0.0% 7d) (-49.8% volume)
Earnings Calendar: 2022-08-11
Market Cap:
http://www.checkmatepharma.com
Sec Filling | Patents | 22 employees
Checkmate Pharmaceuticals, Inc. is a clinical-stage biotechnology company. It engages in developing and commercializing proprietary technology to harness the power of the immune system to combat cancer. It specializes in the field of CpG oligonucleotides. The company was founded by Arthur M. Krieg and Chuck Yo in July 2015 and is headquartered in Cambridge, MA.
cancer
add to watch list Paper trade email alert is off
ChemoCentryx, Inc.
CCXI
|
$51.99
-0.04%
|
Health Technology
(0.0% 1d) (0.0% 1m) (0.0% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (160.14% volume)
Earnings Calendar: 2022-11-08
Market Cap: $ 3,709,791,785
http://www.chemocentryx.com
Sec Filling | Patents | 82 employees
(US) ChemoCentryx, Inc. is a biopharmaceutical company engages in the development and commercialization of medicines. It focuses on inflammatory disorders, autoimmune diseases, and cancer. Its drug candidates such as Avacopan and CCX140, selectively blocks a specific chemoattractant receptor, leaving the rest of the immune system intact. The company was founded by Thomas J. Schall in 1997 and is headquartered in Mountain View, CA.
cancer autoimmunity
add to watch list Paper trade email alert is off
9 Meters Biopharma, Inc.
NMTR
|
$0.0722
-42.97%
-67.9%
10M
|
Health Technology
(0.0% 1d) (0.0% 1m) (-94.2% 1y) (0.0% 2d) (0.0% 3d) (-43.0% 7d) (254.86% volume)
Earnings Calendar: 2023-08-14
Market Cap: $ 1,043,990
http://www.innovatebiopharma.com
Sec Filling | Patents | 8 employees
(US) 9 Meters Biopharma, Inc. is a clinical-stage biopharmaceutical company. It focuses on developing novel medicines for autoimmune inflammatory disease. The company is founded by Jay P. Madan and Kendyle Woodard in 2012 and is headquartered in Raleigh, NC.
autoimmunity
add to watch list Paper trade email alert is off
Acer Therapeutics Inc.
ACER
|
$0.9
-3.61%
420K
|
Health Technology
(0.0% 1d) (0.0% 1m) (-12.6% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (1077.06% volume)
Earnings Calendar: 2022-11-14
Market Cap: $ 22,017,353
http://www.acertx.com
Sec Filling | Patents | 17 employees
(US) Acer Therapeutics, Inc. is a pharmaceutical company. The firm engages in the acquisition, development and commercialization of therapies for medical needs. Its product pipeline includes Edsivo and ACER-001. The Edsivo is a type of celiprolol for Vascular Ehlers-Danlos syndrome. The ACER-001 is for the treatment of urea cycle disorders and Maple Syrup Urine diseases. The company was founded by Christopher Schelling on September 19, 2017 and is headquartered in Newton, MA.
acquisitions urine urea treatment
add to watch list Paper trade email alert is off
Aerie Pharmaceuticals, Inc.
AERI
|
$15.25
0.0%
|
Health Technology
(0.0% 1d) (0.0% 1m) (0.0% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (13.48% volume)
Earnings Calendar: 2023-02-23
Market Cap: $ 753,615,457
http://www.aeriepharma.com
Sec Filling | Patents | 380 employees
(US) Aerie Pharmaceuticals, Inc. engages in the discovery, development, and commercialization of therapies for the treatment of patients with open-angle glaucoma, retinal diseases and other diseases of the eye. Its products include Rhopressa, Roclatan, AR-13503, and AR-1105. The company was founded by David L. Epstein, Casey C. Kopczynski, Thomas J. van Haarlem, and Eric J. Toone on June 22, 2005 and is headquartered in Durham, NC.
eye treatment
Drugs
Rhopressa (netarsudil)Rocklatan (netarsudil and latanoprost ophthalmic solution, 0.02%/0.005%)
add to watch list Paper trade email alert is off
Allied Healthcare Products, Inc.
AHPI
|
$0.5501
0
|
Health Technology
(0.0% 1d) (0.0% 1m) (0.0% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (-66.19% volume)
Earnings Calendar:
Market Cap: $ 2,207,847
http://www.alliedhpi.com
Sec Filling | Patents | 218 employees
Allied Healthcare Products, Inc. manufactures, markets, and distributes a variety of respiratory products used in the health care industry to hospitals, hospital equipment dealers, hospital construction contractors, home health care dealers, and emergency medical product dealers. Its products include respiratory care products, medical gas equipment, and emergency medical products. The company was founded in 1979 and is headquartered in St. Louis, MO.
respiratory construction
add to watch list Paper trade email alert is off
Medigus Ltd.
MDGS
|
$2.48
13.78%
12.11%
25K
|
Health Technology
(0.0% 1d) (-14.0% 1m) (-60.5% 1y) (0.0% 2d) (0.0% 3d) (5.8% 7d) (174.81% volume)
Earnings Calendar:
Market Cap: $ 25,325,336
http://www.medigus.com
Sec Filling | Patents | 20 employees
(IL) Medigus Ltd. engages in research and development of medical treatment for the gastrointestinal tract. Its product is the MUSE system, an endoscopic device to perform Transoral Fundoplication for the treatment of gastroesophageal reflux disease. The company was founded by Elazar Sonnenschein on December 9, 1999 and is headquartered in Omer, Israel.
gastrointestinal endoscopy israel treatment
add to watch list Paper trade email alert is off
Nabriva Therapeutics plc
NBRV
|
$1.42
1.39%
720K
|
Health Technology
(0.0% 1d) (0.0% 1m) (-13.4% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (3702.73% volume)
Earnings Calendar: 2023-08-03
Market Cap: $ 4,546,068
http://www.nabriva.com
Sec Filling | Patents | 162 employees
(IE) Nabriva Therapeutics Plc is a biopharmaceutical company, which engages in the research, development and commercialization of novel anti-infective agents to treat serious infections. Its product pipeline includes Lefamulin, and CONTEPO. The company was founded in October 2005 and is headquartered in Dublin, Ireland.
antibiotics pleuromutilin antibiotic antibacterial injection
add to watch list Paper trade email alert is off
NanoString Technologies, Inc.
NSTG
|
$0.1053
-37.43%
-0.19%
0
|
Health Technology
(0.0% 1d) (0.0% 1m) (-99.0% 1y) (0.0% 2d) (0.0% 3d) (-37.4% 7d) (-60.48% volume)
Earnings Calendar: 2024-02-27
Market Cap: $ 5,066,858
http://www.nanostring.com
Sec Filling | Patents | 551 employees
(US) NanoString Technologies, Inc. engages in the development and commercialization of instrument and services for profiling of genes and proteins from tissue sample. It offers GeoMx Digital Spatial Profiler, nCounter Systems, analysis solutions, gene expression panels, Vantage 3D Assays, miRNA Assays, custom solutions, and Sample Prep and nCounter Consumables. The company was founded by Amber Ratcliffe, Krassen Dimitrov, and Dwayne Dunaway on June 20, 2003 and is headquartered in Seattle, WA.
3d profitable
add to watch list Paper trade email alert is off
Humanigen, Inc.
HGEN
|
$0.0361
-61.5%
120M
|
Health Technology
(0.0% 1d) (0.0% 1m) (-80.1% 1y) (0.0% 2d) (0.0% 3d) (-81.1% 7d) (23283.32% volume)
Earnings Calendar: 2022-11-09
Market Cap: $ 4,298,793
http://www.humanigen.com
Sec Filling | Patents | 2 employees
(US) Humanigen, Inc. is a clinical-stage biopharmaceutical company. It engages in the development of cell and gene therapies for the treatment of cancers through novel human granulocyte-macrophage colony-stimulating factor neutralization and gene-knockout platforms. The company was founded by Jeng-Horng Her & Robert F. Balint on March 15, 2000 and is headquartered in Burlingame, CA.
cancer gene therapies t-cell treatment ceiling
add to watch list Paper trade email alert is off
ImmunoGen, Inc.
IMGN
|
$31.23
0.03%
49M
|
Health Technology
(0.0% 1d) (0.0% 1m) (652.8% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (-100.0% volume)
Earnings Calendar: 2024-02-29
Market Cap: $ 8,315,433,277
http://www.immunogen.com
Sec Filling | Patents | 75 employees
(US) ImmunoGen, Inc. engages in the discovery and development of antibody-drug conjugates to improve outcomes for cancer patients. Its pipeline includes Mirvetuximab Soravtansine, IMGN632, IMGC936, and IMGN151. The company was founded in March 1981 and is headquartered in Waltham, MA.
cancer antibody
add to watch list Paper trade email alert is off
IMV Inc.
IMV
|
$0.8225
-2.74%
45K
|
Health Technology
(0.0% 1d) (0.0% 1m) (22.8% 1y) (-2.5% 2d) (-2.5% 3d) (0.0% 7d) (-76.64% volume)
Earnings Calendar: 2023-05-12
Market Cap: $ 9,632,821
http://www.imv-inc.com
Sec Filling | Patents | n/a employees
IMV, Inc. is a clinical-stage biopharmaceutical company that engages in providing a novel class of cancer immunotherapies and vaccines against infectious diseases including COVID-19. The company leverages its delivery platform (DPX) that programs immune cells directly within the human body to produce robust and sustained target killing capabilities. Its drug candidate, DPX-Survivac, is a targeted T cell therapy that has completed multiple phases 1 and 1b trials generating results in late-stage ovarian cancer and relapsed/refractory DLBCL (Diffuse Large B Cell Lymphoma) where it has identified a predictive biomarker. The company was founded by Warwick Kimmins and Brian E. Lowe on May 18, 2007 and is headquartered in Dartmouth, Canada.
vaccine covid cancer ovarian cancer immunotherapy infectious disease glass t-cell ceiling
add to watch list Paper trade email alert is off
InVivo Therapeutics Holdings Corp.
NVIV
|
$0.3207
-25.16%
1.9M
|
Health Technology
(0.0% 1d) (0.0% 1m) (-62.6% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (-98.2% volume)
Earnings Calendar:
Market Cap: $ 995,917
http://www.invivotherapeutics.com
Sec Filling | Patents | 6 employees
(US) Invivo Therapeutics Holdings Corp. operates as a research and clinical-stage biotechnology company, which engages in developing and commercializing biopolymer scaffolding devices for the treatment of spinal cord injuries. Its clinical development program is the Neuro-Spinal Scaffold implant, which is an investigational bioresorbable polymer scaffold that is designed for implantation at the site of injury within a spinal cord. The company was founded by Joseph P. Vacanti, Frank M. Reynolds, and Robert Langer in January 2005 and is headquartered in Cambridge, MA.
spinal cord msa treatment
add to watch list Paper trade email alert is off
Reata Pharmaceuticals, Inc.
RETA
|
$172.36
0.02%
0.03%
0
|
Health Technology
(0.0% 1d) (0.0% 1m) (72.6% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (165.53% volume)
Earnings Calendar: 2023-11-07
Market Cap: $ 5,789,158,047
http://www.reatapharma.com
Sec Filling | Patents | 220 employees
(US) Reata Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in identifying, developing, and commercializing pharmaceutical products. Its product candidates are bardoxolone methyl and omaveloxolone, which activate the transcription factor Nrf2 to restore mitochondrial function, reduce oxidative stress, and resolve inflammation. The company was founded by W. Christian Wigley, Waldemar Priebe, Philip J. Thomas, Jef Karel de Brabander, Thomas C. Südhof, Jonathan M. Graff and J. Warren Huff on September 1, 2002 and is headquartered in Irving, TX.
education
add to watch list Paper trade email alert is off
SeaSpine Holdings Corporation
SPNE
|
$9.54
8.29%
-1.99%
|
Health Technology
(0.0% 1d) (0.0% 1m) (0.0% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (314.37% volume)
Earnings Calendar: 2023-03-10
Market Cap: $ 354,914,712
http://www.seaspine.com
Sec Filling | Patents | 386 employees
(US) SeaSpine Holdings Corp. is a medical technology company, which engages in the design, development, and commercialization of surgical solutions for the treatment of patients suffering from spinal disorders. It products include thoracolumbar hardware, cervical hardware, orthobiologics, and spine pure strip. The company was founded on February 12, 2015 and is headquartered in Carlsbad, CA.
treatment
add to watch list Paper trade email alert is off
Turning Point Therapeutics, Inc.
TPTX
|
$76.01
-0.03%
|
Health Technology
(0.0% 1d) (0.0% 1m) (0.0% 1y) (0.0% 2d) (0.0% 3d) (0.7% 7d) (NaN% volume)
Earnings Calendar: 2022-11-08
Market Cap: $ 3,806,145,795
http://www.tptherapeutics.com
Sec Filling | Patents | 95 employees
Turning Point Therapeutics, Inc. engages in the discovery and development of precision medicines for cancer and other diseases. Its product pipeline include Repotrectinib, TPX-0022, TPX-0046, and TPS-O131, a next-gen ALK inhibitor. The company was founded by J. Jean Cui and Y. Peter Li in October 2013 and is headquartered in San Diego, CA.
cancer
add to watch list Paper trade email alert is off
Your Today's Watch List
Sign in to create a watchlistGainers vs Losers
| 71% | 29% |
Top 10 Gainers
AGBA | News | $1.27 217.5% 120M
|
Finance
EGOX | $0.0503 39.72% 320M
|
RWOD | $10.52 31.56% 5.9M
|
n/a
ZCMD | $1.905 31.38% 30M
|
Commercial Services
MRDB 4 | $0.536 27.65% 2M
|
n/a
BSFC | $0.0822 27.64% 75M
|
Manufacturing
TPET | $0.4121 25.68% 45M
|
n/a
NVFY | $2.65 25.59% 33M
|
Consumer Durables
INDO | $5.1 25.0% 15M
|
Energy Minerals
CHRO | $1.53 24.9% 100K
|
n/a
Last 48 Hours Insiders Buying
CLSD | $1.42 7.58% 170K
|
Health Technology
|
14:00
CDZI P 25000 | $2.255 0.22% 160K
|
Utilities
|
14:00
ETST P 39000 | $0.068 43K
|
Manufacturing
|
13:30
FNLC P 1275 | $22.91 3.38% 13K
|
Finance
|
12:30
ADMQ | $0.0532 480K
|
|
10:30
AXR P 2400 | $20.99 -5.32% 11K
|
Finance
|
21:00
QCRH P 118 | $56.88 2.65% 23K
|
Finance
|
18:01
VUZI P 7500 | $1.225 -2.78% 410K
|
Electronic Technology
|
18:00
RMCF | $3.69 3.94% 9.5K
|
Consumer Non-Durables
|
20:10